European Commission 18 December 2015, Commission Decision of 18/12/2015 declaring a concentration to be compatible with the common market (Case No COMP/M.7872 - NOVARTIS / GSK (OFATUMUMAB OUTOIMMUNE INDICATIONS)) according to Council Regulation (EC) No 139/2004 (Only the English text is authentic)

EUROPEAN COMMISSION Brussels, 18.12.2015 C(2015) 9710 final To the notifying party: Dear Sir/Madam, Subject: Case M.7872 – Novartis / GlaxoSmithKline (ofatumumab autoimmune indications) Commission decision pursuant to Article 6(1)(b) of Council Regulation No 139/2004 and Article 57 of the Agreement on the European Economic Area On 18 November 2015, the European Commission received notification of